Wound treatment developed by Geistlich receives key authorization


Wolhusen LU - Geistlich Pharma has developed a treatment to heal complex wounds: Derma-Gide. The product has now received a special authorization in the USA. This will allow it to be used in veteran hospitals and practices.


Geistlich Pharma has achieved “an important milestone” for its Derma-Gide product, as revealed in a press release issued by the company. In this context, the Derma-Gide has been included in the Federal Supply Schedule (FSS) of the US General Services Administration (GSA). This listing means that the product can be procured by veteran hospitals and practices across the USA.


Derma-Gide was developed as a treatment to heal complex wounds. According to information in the Geistlich Pharma press release, the product mimics the structural organization of human skin, thereby providing the basis for cell ingrowth. The Derma-Gide has already been approved by the US Food and Drug Administration (FDA) for ailments such as diabetic foot ulcers, venous leg ulcers, surgical wounds in addition to first and second-degree burns.


The new product also received further recognition in the USA this year after being named as one of the ten most important innovations in the July edition of “PodiatryToday”, a scientific journal with a focus on podiatric medicine.


Geistlich Pharma specializes in biomaterials for the regeneration of bone, cartilage and tissue. The company is headquartered in Wolhusen in the canton of Lucerne, while it also forms part of the Geistlich Group based in Schlieren in the canton of Zurich.

Gestlich Pharma

Back to overview